Plasma changes of calcitonin gene-related peptide and substance P in patients with dialysis headache

Cephalalgia

Volumn 26, Issue 11, 2006, Pages 1287-1293

  Alessandri, M ^a,b   Massanti, L ^b   Geppetti, P ^c   Bellucci, G ^b   Cipriani, M ^b   Fanciullacci, M ^c  

^a Misericordia Hospital ^*  (Italy)

^b MISERICORDIA HOSPITAL   (Italy)

^c UNIVERSITY OF FLORENCE   (Italy)

Author keywords

Calcitonin gene related peptide; Dialysis headache; Substance P; Trigeminovascular system

Indexed keywords

CALCITONIN GENE RELATED PEPTIDE; SUBSTANCE P;

ADULT; AGED; ARTERIOVENOUS FISTULA; ARTICLE; BLOOD SAMPLING; CHEMICAL ANALYSIS; CLINICAL ARTICLE; CONTROLLED STUDY; DISEASE PREDISPOSITION; FEMALE; HEADACHE; HEMODIALYSIS; HUMAN; MALE; RADIOIMMUNOASSAY;

ADULT; AGED; CALCITONIN GENE-RELATED PEPTIDE; FEMALE; HEADACHE; HUMANS; MALE; MIDDLE AGED; RADIOIMMUNOASSAY; RENAL DIALYSIS; SUBSTANCE P;

EID: 33750300699     PISSN: 03331024     EISSN: 14682982     Source Type: Journal    
DOI: 10.1111/j.1468-2982.2006.01217.x     Document Type: Article

References (46)

1. Headache Classification Subcommittee of the International Headache Society. The international classification of headache disorders. Cephalalgia 2004; 24 (Suppl. 1):1-160.
2. Bana DS, Yap AU, Graham JR. Headache during hemodialysis. Headache 1972; 12:1-14.
3. Arieff AI. Dialysis disequilibrium syndrome: current concepts on pathogenesis and prevention. Kidney Int 1994; 45:629-35.
4. Pappius HM, Dossetor JB. The effects of rapid hemodialysis on brain tissues and cerebrospinal fluid of dogs. Can J Physiol Pharmacol 1967; 45:129-47.
5. Silver SM, DeSimone JA, Smith DA, Sterns RH. Dialysis disequilibrium syndrome (DDS) in the rat: role of the 'reverse urea effect'. Kidney Int 1992; 42:161-6.
6. La Greca G, Biasioli S, Chiaramonte S, Dettori P, Fabris A, Feriani M et al. Studies on brain density in hemodialysis and peritoneal dialysis. Nephron 1982; 31:146-50.
7. Leinisch-Dahlke E, Schmidt-Wilcke T, Krämer BK, May A. Improvement of dialysis headache after treatment with ACE-inhibitors but not angiotensin II receptor blocker: a case report with pathophysiological considerations. Cephalalgia 2005; 25:71-4.
8. Penfield W. A contribution to the mechanisms of intracranial pain. Assoc Res Nerv Ment Dis 1935; 15:399-416.
9. Ray BS, Wolff HG. Experimental studies on headaches, pain sensitive structures of the head and their significance in headaches. Arch Surg 1940; 41:813-46.
10. Mayberg MR, Zervas NT, Moskowitz MA. Trigeminal projections to supratentorial pial and dural blood vessels in cats demonstrated by horseradish peroxidase histochemistry. J Comp Neurol 1984; 223:46-56.
11. Arbeb MAR, Wiklind L, Scendgaard NA. Origin and distribution of cerebral vascular innervation from superior cervical, trigeminal and spinal ganglia investigated with retrograde and anterograde WGA-HRP tracing in the rat. Neuroscience 1986; 19:695-708.
12. Uddman R, Edvinsson L, Ekman R, McCulloch J, Kingmann TA. Innervation of the feline cerebral vasculature by nerve fibres containing calcitonin gene-related peptide: trigeminal origin and co-existence with substance P. Neurosci Lett 1985; 62:131-6.
13. Goadsby PJ, Edvinsson L, Ekman R. Release of vasoactive peptides in the extracerebral circulation of man and the cat during activation of the trigeminovascular system. Ann Neurol 1988; 23:193-6.
14. Moskowitz MA, Macfarlane R. Neurovascular and molecular mechanisms in migraine headaches. Cerebrovasc Brain Metab Rev 1993; 5:159-77.
15. Goadsby PJ, Edvinsson L, Ekmann R. Vasoactive peptide release in the extracerebral circulation of humans during migraine headache. Ann Neurol 1990; 28:183-7.
16. Gallai V, Sarchielli P, Floridi A, Franceshini M, Codini M, Trequattrini A, Palombo R. Vasoactive peptide levels in the plasma of young migraine patients with and without aura assessed both interictally and ictally. Cephalalgia 1995; 5:426-32.
17. Goadsby PJ, Edvinsson L. Human in vivo evidence for trigeminovascular activation in cluster headache. Brain 1994; 117:427-34.
18. Fanciullacci M, Alessandri M, Figini M, Geppetti P, Michelacci S. Increase in plasma calcitonin gene-related peptide from the extracerebral circulation during nitroglycerin-induced cluster headache attack. Pain 1995; 60:119-23.
19. Fanciullacci M, Alessandri M, Sicuteri R, Marabini S. Responsiveness of the trigeminovascular system to nitroglicerine in cluster headache patients. Brain 1997; 120:283-8.
20. Goadsby PJ, Edvinsson L. Neuropeptide changes in a case of chronic paroxysmal hemicrania. Evidence for trigemino-parasympathetic activation. Cephalalgia 1996; 16:448-50.
21. Lassen LH, Haderslev PA, Jacobsen VB, Iversen HK, Sperling B, Olesen J. CGRP may play a causative role in migraine. Cephalalgia 2002; 22:54-61.
22. Olesen J, Diener H-C, Husstedt IW, Goadsby PJ, Hall D, Meier U et al. Calcitonin gene-related peptide receptor antagonist BIBN 4096 BS for the acute treatment of migraine. N Engl J Med 2004; 350:1104-10.
23. Geppetti P, Frilli S, Renzi D, Santicioli P, Maggi CA, Theodorsson E, Fanciullacci M. Distribution of calcitonin gene-related peptide-like immunoreactivitry in various rat tissues: correlation with substance P and other tachykinins and sensitivity to capsaicin. Regul Pept 1988; 23:289-98.
24. Antoniazzi AL, Bigal ME, Bordini CA, Tepper SJ, Speciali JG. Headache and haemodialysis: a prospective study. Headache 2003; 43:99-102.
25. Göksan B, Karaali-Savrun F, Ertan S, Savrun M. Haemodialysis-related headache. Cephalalgia 2004; 24:284-7.
26. Edvinsson L, Jansen I, Cuhna e Sá M, Gulbenkian S. Demonstration of neuropeptide-containing nerves and vasomotor responses to perivascular peptides in human cerebral arteries. Cephalalgia 1994; 14:88-96.
27. Jansen-Olesen I, Mortensen A, Edvinsson L. Calcitonin gene-related peptide is released from capsaicin-sensitive nerve fibres and induces vasodilatation of human cerebral arteries concomitant with activation of adenyl cyclase. Cephalalgia 1996; 16:310-6.
28. Williamson DJ, Hargreaves RJ, Hill RG, Shepheard LS. Intravital microscope studies on the effects of neurokinin agonists and calcitonin gene-related peptide on dural blood vessel diameter in the anaesthetized rat. Cephalalgia 1997; 17:518-24.
29. Moskowitz MA. Neurogenic inflammation in the pathophysiology and treatment of migraine. Neurology 1993; 43:16-20.
30. Odar-Cederlöf I, Theodorsson E, Ericsson F, Kjellstrand CM. Plasma concentrations of calcitonin gene-related peptide in fluid overload. Lancet 1991; 338:411-2.
31. Ashina M, Bendtsen L, Jensen R, Schifter S, Jansen-Olesen I, Olesen J. Plasma levels of calcitonin gene-related peptide in chronic tension-type headache. Neurology 2000; 55:1335-9.
32. Wimalawansa SJ. Calcitonin gene-related peptide and its receptors: molecular genetics, physiology, pathophysiology, and therapeutic potentials. Endocr Rev 1996; 17:533-85.
33. Vanholder R, De Smet R, Vogeleere P, Ringoir S. Middle molecules: toxicity and removal by hemodialysis and related strategies. Artif Organs 1995; 19:1120-5.
34. Niwa T, Fujishiro T, Uema K, Tsuzuki T, Tominaga Y, Emoto Y et al. Effect of hemodialysis on plasma levels of vasoactive peptides: endothelin, calcitonin gene-related peptide and human atrial natriuretic peptide. Nephron 1993; 64:552-9.
35. Hegbrant J, Thysell H, Mårtensson L, Ekman R, Boberg U. Changes in plasma levels of vasoactive peptides during standard bicarbonate hemodialysis. Nephron 1993; 63:303-8.
36. Chang MM, Leeman SE, Niall HD. Amino-acid sequence of substance P. Nat New Biol 1971; 232:86-7.
37. Erspamer V. Amphibian skin peptides in mammals - looking ahead. Trends Neurosci 1983; 6:200-1.
38. Harrison S, Geppetti P. Substance P. Int J Biochem Cell Biol 2001; 33:555-76.
39. Otsuka M, Yoshioka K. Neurotransmitter function of mammalian tachykinins. Physiol Rev 1993; 73:229-308.
40. Edvinsson L, Rosendal-Helgesen S, Uddman R. Substance P: localization, concentration and release in cerebral arteries, choroid plexus and dura mater. Cell Tissue Res 1983; 234:1-7.
41. Nakano T, Shimomura T, Takahashi K, Ikawa S. Platelet substance P and 5-hydroxytriptamine in migraine and tension-type headache. Headache 1993; 33:528-32.
42. Mazzotta G, Sarchielli P, Gaggioli A, Gallai V. Study of pressure pain and cellular concentration of neurotransmitters related to nociception in episodic tension-type headache patients. Headache 1997; 37:565-71.
43. Marukawa H, Shimomura T, Takahashi K. Salivary substance P, 5-hydroxytriptamine and gamma-aminobutyric acid levels in migraine and tension-type headache. Headache 1996; 36:100-4.
44. Ashina M, Bendtsen L, Jensen R, Ekman R, Olesen J. Plasma levels of substance P, neuropeptide Y and vasoactive intestinal polypeptide in patients with chronic tension-type headache. Pain 1999; 83:541-7.
45. Nicolodi M, Del Bianco E. Sensory neuropeptides (substance P, calcitonin gene-related peptide) and vasoactive intestinal polipeptide in human saliva: their pattern in migraine and cluster headache. Cephalalgia 1990; 10:39-50.
46. Sicuteri F, Fanciullacci M, Geppetti P, Renzi D, Caleri D, Spillantini MG. Substance P mechanisms in cluster headache: evaluation in plasma and cerebrospinal fluid. Cephalalgia 1985; 5:143-9.